On June 1, 2026, Edgewise Therapeutics, Inc. announced an agreement with Servier Pharmaceuticals to sell its neuromuscular program and assets for $1.55 billion, plus potential milestone payments of up to $1.2 billion upon achieving specific approvals and sales targets.